The Conference on Retroviruses and Opportunistic Infections (CROI) takes place virtually from February 12-16. The entire program will be accessible live and via on-demand playback to all registered attendees through the conference platform. HPTN researchers will present 10 abstracts (six oral; four posters) covering HPTN 069, HPTN 071, HPTN 082, HPTN 083, HPTN 084, HVTN 130/HPTN 089, HPTN Modelling Centre, and CoVPN 5002.
Presentations will be shared online when available at hptn.org/presentedresearch.
See below for abstract listings.
Study |
Study # and Title |
Presenter(s) |
Presentation Details |
Monday, February 14 |
|||
| CoVPN 5002 | 46 - SARS-CoV-2 Prevalence in Children and Adults in 15 US Communities: The COMPASS Study | Jessica E. Justman |
Oral Abstract Session 4 Evolving Epidemiology of HIV and SARS-CoV-2 9:45 AM MT - 11:45 AM MT (10:14) |
| HPTN Modelling Centre | 836 - Estimating Benefits From Using On-Demand Oral PrEP by MSM in US: A Modeling Study | Sarah Stansfield |
Poster Session V01 PrEP: Services, Cost-Effectiveness, Bone Loss, and ARV Resistance 2:00 PM MT - 3:30 PM MT |
Tuesday, February 15 |
|||
| HVTN 405/HPTN 1901 | 97 - Symptom Durating in COVID-19 Convalescent Patients: Regional & Clinical Associations | Jorge A. Gallardo-Cartagena |
Oral Abstract Session 9 SARS-CoV-2 Antivirals and outcomes 9:45 AM MT - 11:45 AM MT (9:50) |
| HVTN 130/HPTN 089 | 81 - Phase 1 Study of Combination Anti-HIV Neutralizing Antibodies in HIV Negative Adults | Magdalena E. Sobieszczyk |
Oral Abstract Session 7 HIV Prevention: from the Bench to Population 9:45 AM MT - 11:45 AM MT (9:58) |
| HPTN 084 | 86 - Counterfactual Estimation of CAB-LA Efficacy Against Placebo Using External Trial Data | Deborah Donnell |
Oral Abstract Session 7 HIV Prevention: from the Bench to Population 9:45 AM MT - 11:45 AM MT (11:01) |
| HPTN 083 | 96 - Updated Efficacy, Safety, and Case Studies in HPTN 083: CAB-LA vs. TDF/FTC for PrEP | Raphael J. Landovitz |
Oral Abstract Session 8 Global Persperctives on HIV Testing, Treatment, and Prevention 9:45 AM MT - 11:45 AM MT (11:01) |
| HPTN 071 | 87 - Different HIV Protection for Traditional and Medical Circumcision in HPTN 071 (POPART) | Kidist B. Zewdie |
Oral Abstract Session 7 HIV Prevention: from the Bench to Population 9:45 AM MT - 11:45 AM MT (11:09) |
| HPTN 083 | 95 - CAB-LA PrEP: Early Detection of HIV Infection may Reduce INSTI Resistance Risk | Susan Eshleman |
Oral Abstract Session 8 Global Perspectives on HIV Testing, Treatment, and Prevention 9:45 AM MT - 11:45 AM MT (11:09) |
| HPTN 082 | 842 - A Tool to Assess HIV Prevention Readiness of Adolescent Girls and Young Women | Geetha Beauchamp |
Poster Session V02 PrEP in Adolescents and Pregnant People 2:00 PM MT - 3:30 PM MT |
Wednesday, February 16 |
|||
| HPTN 069 | 859 - Expectations of Preventive Benefits and HIV-Related Risk Behaviors in HPTN 069 | Jeremy Sugarman |
Poster Session V04 Early Phase Studies of HIV Vaccines, bNAbs, and Next-Generation PrEP 2:00 PM MT - 3:30 PM MT |
| HPTN 084 | 700 - Evaluation of CAB-LA Safety and PK in Pregnant Women in the Blinded Phase of HPTN 084 | Sinead Delany-Moretlwe |
Poster Session P05 HIV Infection and Prevention in Pregnancy 2:00 PM MT - 3:30 PM MT |